

license . . . suspended [or] revoked . . . by competent State authority and is no longer authorized by State law to engage in the . . . dispensing of controlled substances.” Also, DEA has long held that the possession of authority to dispense controlled substances under the laws of the State in which a practitioner engages in professional practice is a fundamental condition for obtaining and maintaining a practitioner’s registration. *See, e.g., James L. Hooper*, 76 FR 71371 (2011), *pet. for rev. denied*, 481 Fed. Appx. 826 (4th Cir. 2012); *see also Frederick Marsh Blanton*, 43 FR 27616 (1978) (“State authorization to dispense or otherwise handle controlled substances is a prerequisite to the issuance and maintenance of a Federal controlled substances registration.”).

This rule derives from the text of two provisions of the CSA. First, Congress defined “the term ‘practitioner’ [to] mean[] a . . . physician . . . or other person licensed, registered or otherwise permitted, by . . . the jurisdiction in which he practices . . . to distribute, dispense, [or] administer . . . a controlled substance in the course of professional practice.” 21 U.S.C. 802(21). Second, in setting the requirements for obtaining a practitioner’s registration, Congress directed that “[t]he Attorney General shall register practitioners . . . if the applicant is authorized to dispense . . . controlled substances under the laws of the State in which he practices.” 21 U.S.C. 823(f). Because Congress has clearly mandated that a practitioner possess state authority in order to be deemed a practitioner under the Act, DEA has long held that revocation of a practitioner’s registration is the appropriate sanction whenever he is no longer authorized to dispense controlled substances under the laws of the State in which he engages in professional practice. *See, e.g., Calvin Ramsey*, 76 FR 20034, 20036 (2011); *Sheran Arden Yeates, M.D.*, 71 FR 39130, 39131 (2006); *Dominick A. Ricci*, 58 FR 51104, 51105 (1993); *Bobby Watts*, 53 FR 11919, 11920 (1988); *Blanton*, 43 FR 27616 (1978).

Based on my finding that the OMBC revoked Respondent’s Osteopathic Physician’s and Surgeon’s License to practice medicine, I find that Respondent is currently without authority to dispense controlled substances under the laws of California, the State in which he is registered. *Accord Christopher D. Owens, M.D.*, 83 FR 13143, 13145 & n.1 (2018) (citing Cal. Health & Safety Code §§ 11024, 11150, 11210, 11352, 2051, 2052). Here, there is no dispute over the material fact

that Respondent is no longer currently authorized to dispense controlled substances in California, the State in which he is registered. Accordingly, Respondent is not entitled to maintain his DEA registration. I will therefore adopt the ALJ’s recommendation that I revoke Respondent’s registration. R.D., at 7. I will also deny any pending application to renew or to modify his registration, or any pending application for any other DEA registration in California, as requested in the Show Cause Order. Order to Show Cause, at 1.

Order

Pursuant to the authority vested in me by 21 U.S.C. 823(f) and 824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of Registration No. BS7367623, issued to Paul Surinder Singh, D.O., be, and it hereby is, revoked. I further order that any pending application of Paul Surinder Singh to renew or modify the above registration, or any pending application of Paul Surinder Singh for any other DEA registration in the State of California, be, and it hereby is, denied. This Order is effective March 13, 2019.

Dated: January 17, 2019.

Uttam Dhillon,

Acting Administrator.

[FR Doc. 2019–01849 Filed 2–8–19; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Application: Almac Clinical Services Incorp (ACSI)

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 13, 2019. Such persons may also file a written request for a hearing on the application on or before March 13, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug

Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on December 28, 2018, Almac Clinical Services Incorp (ACSI), 25 Fretz Road, Souderton, Pennsylvania 18964 applied to be registered as an importer of the following basic class of controlled substance:

Controlled substance	Drug code	Schedule
Psilocybin	7437	I

The company plans to import the controlled substance in packaged dosage forms for clinical trials for one customer.

Dated: January 30, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019–01861 Filed 2–8–19; 8:45 am]

BILLING CODE 4410–09–P

NATIONAL CAPITAL PLANNING COMMISSION

Notice of Memorandum of Agreement

AGENCY: National Capital Planning Commission.

ACTION: Notice of Memorandum of Agreement Between the National Capital Planning Commission and the Smithsonian Institution.

SUMMARY: The National Capital Planning Commission (NCP) and the Smithsonian Institution (Smithsonian) have entered into a Memorandum of Agreement (MOA) effective December

20, 2018. The MOA details the process the two agencies will follow to comply with the National Environmental Policy Act (NEPA) 42 U.S.C. 4371). NCPC has a NEPA obligation for projects submitted by the Smithsonian to NCPC for review and approval. The Smithsonian is not considered a federal agency for NEPA purposes and has no NEPA obligation. The MOA is required by NCPC's NEPA Regulations (1 CFR part 601) to establish a cooperative working relationship between the parties to ensure NCPC's compliance with NEPA. A copy of the MOA is online at NCPC's website at the following location: https://www.ncpc.gov/docs/MOA_NCPC_Smithsonian_NEPA_December2018.pdf.

FOR FURTHER INFORMATION CONTACT:

Diane Sullivan, Director, Urban Design and Plan Review Division at (202) 482-7244 or diane.sullivan@ncpc.gov.

Authority: 42 U.S.C. 4371, 1 CFR 601.5(b).

Dated: February 5, 2019.

Anne Schuyler,
General Counsel.

[FR Doc. 2019-01710 Filed 2-8-19; 8:45 am]

BILLING CODE P

**NATIONAL CREDIT UNION
ADMINISTRATION**

**Sunshine Act: Notice of Agency
Meeting**

TIME AND DATE: 10:00 a.m., Thursday, February 14, 2019.

PLACE: Board Room, 7th Floor, Room 7047, 1775 Duke Street (All visitors must use Diagonal Road Entrance), Alexandria, VA 22314-3428.

STATUS: Open.

MATTERS TO BE CONSIDERED:

1. Board Briefing, Loans in Areas Having Special Flood Hazards.
2. NCUA Rules and Regulations, Supervisory Committee Audits.

RECESS: 10:30 a.m.

TIME AND DATE: 11:00 a.m., Thursday, February 14, 2019.

PLACE: Board Room, 7th Floor, Room 7047, 1775 Duke Street, Alexandria, VA 22314-3428.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Creditor Claim Appeal. Closed pursuant to Exemption (6).
2. Creditor Claim Appeal. Closed pursuant to Exemption (6).

FOR FURTHER INFORMATION CONTACT:

Gerard Poliquin, Secretary of the Board, Telephone: 703-518-6304.

Gerard Poliquin,

Secretary of the Board.

[FR Doc. 2019-02099 Filed 2-7-19; 4:15 pm]

BILLING CODE 7535-01-P

NATIONAL SCIENCE FOUNDATION

**Proposal Review Panel for Materials
Research; Notice of Meeting**

In accordance with the Federal Advisory Committee Act (Pub. L. 92-463, as amended), the National Science Foundation announces the following meeting:

Name and Committee Code:

University of Illinois at Urbana-Champaign MRSEC 2nd year Site Visit (1203).

Date and Time: Tuesday, May 21, 2019; 7:30 a.m.–3:45 p.m.

Place: University of Illinois (Urbana-Champaign), 1304 W Green St. Urbana, IL 61801.

Type of Meeting: Part-Open.

Contact Person: Dr. Daniele Finotello, Program Director, Division of Materials Research, National Science Foundation, 2415 Eisenhower Avenue, Room W 9216, Alexandria, VA 22314; Telephone: (703) 292-4432.

Purpose of Meeting: Site visit to provide an evaluation of the progress of the projects at the host site for the Division of Materials Research at the National Science Foundation.

Agenda

May 21, 2019:

07:30 a.m.–08:30 a.m	Breakfast—NSF PDs and Site Visit Team	OPEN.
08:30 a.m.–09:00 a.m	Transfer to Meeting Site, Introductions, Setup	OPEN.
09:00 a.m.–09:45 a.m	Directors Overview	OPEN.
09:45 a.m.–10:00 a.m	Discussion	OPEN.
10:00 a.m.–10:25 a.m	IRG-1 Presentation	OPEN.
10:25 a.m.–10:30 a.m	IRG-1 Discussion	OPEN.
10:30 a.m.–10:45 a.m	Break	OPEN.
10:45 a.m.–11:10 a.m	IRG-2 Presentation	OPEN.
11:10 a.m.–11:15 a.m	RG-2 Discussion	OPEN.
11:15 a.m.–11:40 a.m	Education and Outreach Presentation	OPEN.
11:40 a.m.–11:45 a.m	Education and Outreach Discussion	OPEN.
11:45 a.m.–12:10 p.m	NSF PDs and Site Visit Team	CLOSED.
12:10 p.m.–01:10 p.m	LUNCH.	
01:15 p.m.–02:15 p.m	Poster Session	OPEN.
02:15 p.m.–02:30 p.m	Panel & NSF Meet MRSEC Director/Exec. Com	OPEN.
02:30 p.m.–03:15 p.m	NSF PDs and Site Visit Team (Closed)	CLOSED.
03:15 p.m.–03:45 p.m	Debriefing	OPEN.
03:45 p.m	Adjourn.	

Reason for Closing: The work being reviewed during closed portions of the site visit include information of a proprietary or confidential nature, including technical information; financial data, such as salaries and personal information concerning individuals associated with the project. These matters are exempt under 5

U.S.C. 552b(c), (4) and (6) of the Government in the Sunshine Act.

Dated: February 6, 2019.

Crystal Robinson,

Committee Management Officer.

[FR Doc. 2019-01870 Filed 2-8-19; 8:45 am]

BILLING CODE 7555-01-P

NATIONAL SCIENCE FOUNDATION

**Proposal Review Panel for Materials
Research; Notice of Meeting**

In accordance with the Federal Advisory Committee Act (Pub. L. 92-463, as amended), the National Science Foundation (NSF) announces the following meeting: